Floatz Rating
B58/100
Confidence
Indicative
Sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06251310CT.gov SW-682 in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04339062CT.gov Cemiplimab in AlloSCT/SOT Recipients With CSCC | — | Completed | — | — | — |
NCT04185883CT.gov Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | — | Active Not Recruiting | — | — | — |
NCT02404051CT.gov Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT02352844CT.gov Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations | — | Completed | — | — | — |
NCT01596140CT.gov Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | — | Completed | — | — | — |
NCT01508104CT.gov Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01482156CT.gov Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01430572CT.gov Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | — | Completed | — | — | — |
NCT01636908CT.gov Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | — | Completed | — | — | — |
Show 9 more trialsShow fewer
NCT01376310CT.gov GSK1120212 Rollover Study | — | Terminated | — | — | — |
NCT01197170CT.gov Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | — | Completed | — | — | — |
NCT01149434CT.gov Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | — | Terminated | — | — | — |
NCT01190241CT.gov Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | — | Terminated | — | — | — |
NCT01055795CT.gov Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors | — | Completed | — | — | — |
NCT00955773CT.gov A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects | — | Completed | — | — | — |
NCT00849550CT.gov Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. | — | Completed | — | — | — |
NCT01226056CT.gov Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets | — | Suspended | — | — | — |
NCT01148628CT.gov Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | P3 | B · 58 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →